$46.89
▼ -0.3% Today
as of Jul 22, 16:55 ET
Last 30 days
Recent Press Releases & News
10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026
BofA Securities Adjusts 10x Genomics Price Target to $46 From $30
Does 10x Genomics (TXG) Leaving Russell Value Indexes Reframe Its Growth Versus Profitability Story?
Overview
52-week range
$8.95
$34
100% of range
Avg surprise (last 3)
+88.5%
Avg reaction (last 2)
+1.2%
50% positive
Latest IV / EM
92%
EM ±21.1% · $45 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.10 | $-0.29 | +65.5% | +72.2% | -1.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.22 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $0.28 | $-0.35 | +180.0% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.36 | $-0.45 | +20.0% | — | +3.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.30 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.32 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.50 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.79 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.53 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | AMC | -$0.23 | $0.28 | -182.1% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $45M | — | $49M | $48M | $49M | — | $45M | $49M |
| Gross profit | $106M | — | $100M | $125M | $105M | — | $106M | $104M |
| Operating income | $-17M | — | $-32M | $30M | $-39M | — | $-41M | $-42M |
| Net income | $-13M | — | $-27M | $35M | $-34M | — | $-36M | $-38M |
| EPS (diluted) | $-0.10 | — | $-0.22 | $0.28 | $-0.28 | — | $-0.30 | $-0.32 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Inventory | $53M | $56M | $62M | $69M | $75M | $83M | $94M | $88M |
| Total current assets | $670M | $684M | $660M | $656M | $580M | $584M | $594M | $579M |
| Total assets | $1.02B | $1.04B | $1.03B | $980M | $903M | $919M | $938M | $930M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $201M | $245M | $242M | $207M | $196M | $209M | $215M | $206M |
| Total equity | $814M | $796M | $785M | $773M | $707M | $710M | $723M | $724M |